Roche Tarceva News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioPharma

By Syndicated Content May 28, 2021 | 2:06 AM (Reuters) – AstraZeneca’s top-selling Tagrisso drug has been approved for use in the European Union to treat patients with a type of early-stage lung cancer, the company said on Friday. The European Commission has approved the lung cancer drug as an add-on treatment for adults diagnosed early enough for the tumour to be surgically removed, and who have a mutation of the EGFR gene, the British drugmaker said. The approval was based on positive results from a late-stage trial called ADAURA, which showed Tagrisso cut the risk of ...

By Reuters Staff 1 Min Read FILE PHOTO: The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski (Reuters) -AstraZeneca Plc said on Wednesday that China’s health regulator expanded the use of Tagrisso, the British drugmaker’s lung cancer treatment, in patients with a type of lung cancer when diagnosed at an early stage. China’s National Medical Products Administration (NMPA) approved Tagrisso as an adjuvant therapy for patients with early-stage lung cancer who have a mutation of the EGFR gene, Astra...

Duluth, MN, USA / 710 AM 98.1 FM WDSM Dec 21, 2020 1:39 AM (Reuters) -AstraZeneca Plc said on Monday that the U.S. drug regulator had approved Tagrisso, the British drugmaker's top selling treatment for another type of lung cancer when diagnosed at an early stage, pushing its potential sales higher. The lung cancer drug has now been approved in the United States for adjuvant treatment of adults diagnosed early enough for the tumour to be surgically removed, and who have a mutation of the EGFR gene, AstraZeneca said. The approval by the U.S. Food and Drug Administration was based on late-stage...